Tarsus Pharmaceuticals (TARS) Stock: Buy, Sell, or Hold?
TARS - Tarsus Pharmaceuticals, Inc. Common Stock
$68.20
-3.88 (-5.38%)
▼
5d:
+0.19%
30d:
-10.22%
90d:
+13.44%
BUY
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 03, 2026
9d
Get Alerted When TARS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TARS shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: TARS shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: TARS is currently trading at $68.20, which is considered oversold relative to its 30-day fair value range of $71.08 to $77.55. From a valuation perspective, the stock is trading at a discount (Forward PE: -136.4) compared to its historical average (34.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TARS is in a uptrend. The price is currently testing key support at $67.65. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: TARS scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $99.80 (+46.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TARS is in a uptrend. The price is currently testing key support at $67.65. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: TARS scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $99.80 (+46.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$71.08 -
$77.55
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
92.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (62/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.4%)
- BULLISH: Trading 46.3% below Wall St target ($99.80)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- BULLISH: Bottoming setup score 62/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$71.08 -
$77.55
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$6.29
(9.2%)
Support & Resistance Levels
Support Level
$67.65
Resistance Level
$76.64
Current Trend
Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-136.40
Wall Street Target
$99.80
(+46.3%)
Revenue Growth (YoY)
69.4%
Profit Margin
-7.7%
PE vs Historical
-136.4 vs 34.7
CHEAP
Share & Embed Analysis
Last updated: October 23, 2026 9:53 PM ET
Data refreshes hourly during market hours. Next update: 10:53 PM
Data refreshes hourly during market hours. Next update: 10:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TARS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 61 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 50 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 48 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 43 HOLD |
|
SNDX
Syndax Pharmaceuticals I… |
STRONG BUY
12 analysts |
$37 | 59 HOLD |
Advanced TARS Option Strategies
Professional options setups generated by AI based on today's TARS price and gamma walls.
